secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001599298-23-000031
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics FY2022 net loss $78.8M; Akeso ivonescimab deal closed with $500M upfront
--------------------------------------------------------------------------------

- Net loss Q4 2022: $19.2M, FY 2022: $78.8M; operating cash outflow FY2022: $41.6M.
- Cash and equivalents at Dec31,2022: $648.6M, up from $71.8M a year ago, driven by financing.
- Completed $500M upfront payment to Akeso for ivonescimab rights in US, Canada, Europe, Japan.
- Rights offering raised $500M gross; proceeds used to repay $401.3M note to CEO Robert Duggan.
- As of Feb28,2023, cash ~$240M including $100M notes; expected to fund operations into H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000031/0001599298-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000031/smmt-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer